abstract |
The present invention relates to substituted 1,2-ethylenediamines of general formula (I) n n n n n n n n n n wherein the groups R 1 to R 15 , A, B, L, i as well as X 1 -X 4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases. |